Comparable stake leader
BlackRock, Inc.
SEC ownership of Sage Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001597553.
Disclosed value leader
BlackRock, Inc.
Comparable rows
7/20
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
7 of 20
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001597553
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Sage Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
7/20
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.2%
13 rows are not safely comparable across share classes.
13D/G row: BlackRock, Inc.
Showing 1-8 of 20 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 7.2%.
7 of 20 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
7.2%
VANGUARD GROUP INC
5.2%
RTW INVESTMENTS, LP
4.9%
BB BIOTECH AG
1.9%
MORGAN STANLEY
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 20 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
|
7.2%
|
$34,471,350
4,425,077 shares
|
$0 | 31 Mar 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
5.2%
|
$29,784,114
3,265,802 shares
|
-$14,339,987 | 30 Jun 2025 |
| RTW INVESTMENTS, LP |
13D/G
|
4.9%
|
$23,388,462
3,002,370 shares
|
$0 | 31 Dec 2024 |
| BB BIOTECH AG |
13D/G
|
1.9%
|
$9,180,538
1,178,503 shares
|
$0 | 13 Jan 2025 |
| MORGAN STANLEY |
13D/G
|
1.6%
|
$7,886,105
1,012,337 shares
|
-$27,503,802 | 28 Feb 2025 |
| FMR LLC |
13D/G
|
0.8%
|
$3,902,130
500,915 shares
|
-$28,169,341 | 28 Feb 2025 |
| HUNTINGTON NATIONAL BANK |
13F
Company
|
0%
|
$9
1 shares
|
— | 30 Jun 2026 |
| Jeffrey M. Jonas |
3/4/5
Director
|
—
mixed-class rows
|
$2,467,446
140,546 shares
mixed-class rows
|
— | 10 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Sage Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Jeffrey M. Jonas
Net 12M change
$0
Latest report
31 Jul 2025
Recent insider transactions for Sage Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.